Arun Manmadhan

Arun Manmadhan

Auto-generated profile, based on publicly available information

Arun Manmadhan

Department of Medicine, Division of Cardiology, NYU Langone, New York, NY

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2016 in eLife
Verified
Journal Article
Open access
AIAsif Jilani Iqbal
Asif Jilani Iqbal
TBTessa Barrett
Tessa Barrett
LTLewis Taylor
Lewis Taylor
EMEileen McNeill
Eileen McNeill
AMArun Manmadhan
Arun Manmadhan
EFEdward A Fisher
Edward A Fisher
Apolipoprotein A1 (apoA1) is the major protein component of high-density lipoprotein (HDL) and has well documented anti-inflammatory properties. To better understand the cellular and molecular basis of the anti-inflammatory actions of apoA1, we explored the effect of acute human apoA1 exposure on the migratory capacity of monocyte-derived cells in vitro and in vivo. Acute (20–60 min) apoA1 treatment induced a substantial (50–90%) reduction in macrophage chemotaxis to a range of chemoattractants. This acute treatment was anti-inflammatory in vivo as shown by pre-treatment of monocytes prior to adoptive transfer into an on-going murine peritonitis model. We find that apoA1 rapidly disrupts membrane lipid rafts, and as a consequence, dampens the PI3K/Akt signalling pathway that coordinates reorganization of the actin cytoskeleton and cell migration. Our data strengthen the evidence base for therapeutic apoA1 infusions in situations where reduced monocyte recruitment to sites of inflammation could have beneficial outcomes.

1 February 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LSLomon So
Lomon So
SYSung Su Yea
Sung Su Yea
JOJean S. Oak
Jean S. Oak
MLMengrou Lu
Mengrou Lu
AMArun Manmadhan
Arun Manmadhan
DFDavid A. Fruman
David A. Fruman
Class IA phosphoinositide 3-kinase (PI3K) is essential for clonal expansion, differentiation, and effector function of B and T lymphocytes. The p110δ catalytic isoform of PI3K is highly expressed in lymphocytes and plays a prominent role in B and T cell responses. Another class IA PI3K catalytic isoform, p110α, is a promising drug target in cancer but little is known about its function in lymphocytes. Here we used highly selective inhibitors to probe the function of p110α in lymphocyte responses in vitro and in vivo. p110α inhibition partially reduced B cell receptor (BCR)-dependent AKT activation and proliferation, and diminished survival supported by the cytokines BAFF and IL-4. Selective p110δ inhibition suppressed B cell responses much more strongly, yet maximal suppression was achieved by targeting multiple PI3K isoforms. In mouse and human T cells, inhibition of single class IA isoforms had little effect on proliferation, whereas pan-class I inhibition did suppress T cell expansion. In mice, selective p110α inhibition using the investigational agent MLN1117 (previously known as INK1117) did not disrupt the marginal zone B cell compartment and did not block T cell-dependent germinal center formation. In contrast, the selective p110δ inhibitor IC87114 strongly suppressed germinal center formation and reduced marginal zone B cell numbers, similar to a pan-class I inhibitor. These findings show that although acute p110α inhibition partially diminishes AKT activation, selective p110α inhibitors are likely to be less immunosuppressive in vivo compared with p110δ or pan-class I inhibitors.

29 January 2021 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
OIOlivia Iskaros
Olivia Iskaros
KMKassandra PharmD Marsh
Kassandra PharmD Marsh
JPJohn BS Papadopoulos
John BS Papadopoulos
AMArun Manmadhan
Arun Manmadhan
TATania PharmD Ahuja
Tania PharmD Ahuja
Intracardiac thrombus (ICT) formation is a common complication of several cardiovascular diseases. Warfarin is recommended for treatment of ICT by guidelines based on observational studies occurring before the advent of nonvitamin K antagonist direct oral anticoagulants (DOACs). We aim to evaluate the current prescribing patterns at our institution and to compare the efficacy and safety profiles of warfarin versus DOACs for ICT. This is a retrospective review of adult patients treated with oral anticoagulation for ICT between May 2013 and December 2019. Our primary end point was complete thrombus resolution. Secondary outcomes included time to resolution of thrombus, treatment failure, and duration of therapy. Safety end points included stroke and systemic embolization (SSE) and bleeding events. A total of 123 patients were included (DOAC n = 61; warfarin n = 62). At baseline, more patients in the DOAC group had anemia [6 (10%) vs. 0 (0%), P = 0.013] and alcohol use disorder [6 (10%) vs. 0 (0%), P = 0.013]. Complete thrombus resolution occurred in 50 (82%) and 46 (74%) patients in the DOAC and warfarin groups, respectively (P = 0.298). There was a shorter time to thrombus resolution in the DOAC group versus the warfarin group {63 days [interquartile range (IQR) 40–138] vs. 123 days [IQR 86–244], P = 0.003}. There were no differences found in SSE or bleeding between the groups [DOAC 11 (19%) vs. warfarin 17 (28%), P = 0.213]. For patients with an ICT, treatment with a DOAC for at least 3 months may be a comparable alternative to warfarin in safety and efficacy.

30 October 2017 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
AMArun Manmadhan
Arun Manmadhan
SMSunil P. Malhotra
Sunil P. Malhotra
CWCatherine R. Weinberg
Catherine R. Weinberg
ARAlex Reyentovich
Alex Reyentovich
LLLarry A. LatsonJr
Larry A. LatsonJr
MSMuhamed Saric
Muhamed Saric
Pulmonary artery intimal spindle cell sarcomas are rare and carry with them a poor prognosis and high rate of recurrence. In extremely rare cases, this tumor can infiltrate the pulmonic valve and manifest as adult-onset pulmonic stenosis. We report an unusual case of a patient with symptomatic, adult-onset severe pulmonic stenosis who was referred for possible balloon valvuloplasty but was subsequently found to have pulmonary artery intimal sarcoma infiltrating the pulmonary valve leading to progressive exertional dyspnea. The presence of adult-onset pulmonic stenosis should prompt the clinician to investigate further as most cases of pulmonic stenosis are congenital in nature and present early in life. Careful diagnostic evaluation in concert with multimodal imaging should take place to arrive at the correct and challenging diagnosis of sarcoma-induced adult-onset severe pulmonic stenosis. Given the poor prognosis and rapid progression of disease, early diagnosis is crucial.

1 January 2016 in Atherosclerosis
Verified
Journal Article
Open access
PDF file
AIA.J. Iqbal
A.J. Iqbal
TBT.J. Barrett
T.J. Barrett
LTL. Taylor
L. Taylor
EME. McNeill
E. McNeill
AMA. Manmadhan
A. Manmadhan
EFE.A. Fisher
E.A. Fisher